Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate and the liver.

K G Tolman, D O Clegg, R G Lee

    The Journal of Rheumatology. Supplement
    |December 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Low-dose methotrexate for rheumatoid arthritis (RA) can cause liver abnormalities in most patients. Serial enzyme elevations and hypoalbuminemia indicate liver disease, which typically develops after two years of therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    RISK-SENSITIVE ANTIPREDATOR BEHAVIOR IN THE TRINIDADIAN GUPPY, POECILIA RETICULATA.

    Ecology·2019
    Same author

    Pollinator-mediated selection on floral morphology: evidence for transgressive evolution in a derived hybrid lineage.

    Journal of evolutionary biology·2013
    Same author

    OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials.

    Osteoarthritis and cartilage·2011
    Same author

    The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.

    Osteoarthritis and cartilage·2009
    Same author

    Translational mini-review series on immunology of vascular disease: inflammation, infections and Toll-like receptors in cardiovascular disease.

    Clinical and experimental immunology·2009
    Same author

    TJ-114 (Sairei-To), an Herbal Medicine in Rheumatoid Arthritis.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
    Same journal

    GRAPPA 2019 Research Recipient Awards Report.

    The Journal of rheumatology. Supplement·2021
    Same journal

    GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

    The Journal of rheumatology. Supplement·2021
    Same journal

    GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

    The Journal of rheumatology. Supplement·2021
    Same journal

    Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

    The Journal of rheumatology. Supplement·2021
    Same journal

    GRAPPA 2020 Update From the Education Committee.

    The Journal of rheumatology. Supplement·2021
    Same journal

    The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

    The Journal of rheumatology. Supplement·2021
    See all related articles

    Area of Science:

    • Hepatology
    • Rheumatology
    • Pharmacology

    Background:

    • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
    • Methotrexate is a common disease-modifying antirheumatic drug (DMARD) used for RA.
    • Liver toxicity is a potential concern with methotrexate therapy.

    Purpose of the Study:

    • To investigate the incidence and predictors of liver abnormalities in RA patients treated with low-dose pulse methotrexate.
    • To identify specific indicators of methotrexate-induced liver disease.

    Main Methods:

    • Liver biopsy analysis in 29 RA patients treated with low-dose pulse methotrexate.
    • Correlation of liver histology with patient demographics, treatment duration, and cumulative methotrexate dose.
    • Monitoring of liver enzyme (aminotransferase, alkaline phosphatase) levels and albumin levels.

    Related Experiment Videos

    Main Results:

    • 76% of patients (22/29) showed liver abnormalities on biopsy; no cases of cirrhosis were observed.
    • No significant differences in age, treatment duration, or cumulative dose were found between patients with and without liver abnormalities.
    • Isolated enzyme elevations did not predict liver disease; serial elevations and hypoalbuminemia were specific indicators.
    • Significant liver disease did not develop before 2 years of therapy or with cumulative doses <1500 mg.

    Conclusions:

    • Low-dose pulse methotrexate can lead to liver abnormalities in a majority of RA patients.
    • Serial monitoring of liver enzymes and albumin levels is crucial for detecting methotrexate-induced liver disease.
    • Early significant liver disease is unlikely within the first two years or below 1500 mg cumulative dose.